Messenger RNA (mRNA) News and Research

RSS

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.

25 Feb 2015

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres break down and once they reach a certain point of degradation, the cell dies. This is one reason that cells are mortal: telomeres only last so long. That is, unless the enzyme telomerase builds new material onto the worn telomeres to reinforce these chromosomal "bumpers". Telomere repair can be a good thing, but in some cases it's not: overactive telomerase can lengthen telomeres until a cell becomes immortal…leading to cancer.

18 Feb 2015

Recipients of The 2015 Protein Society Awards announced

The Protein Society, the premiere international society dedicated to supporting protein research, announces the winners of The 2015 Protein Society Awards. The awards will be conferred at the 29th Annual Symposium of The Protein Society (July 22-25, 2015, Barcelona, Spain).

5 Feb 2015

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy (DMD) using RNA "surgery".

4 Feb 2015

Two genetic mutations can interact to reduce risk for heart attack

Researchers have determined that two mutations on a single gene can interact in a way that lowers the carrier's risk for a heart attack.

4 Feb 2015

Clusters of gene-blocking microRNAs can limit spread of cancer

Cancers that have spread throughout the body, a process known as metastasis, are difficult, often impossible, to control. They are the leading cause of cancer-related deaths.

4 Feb 2015

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464.

2 Feb 2015

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country.

31 Jan 2015

Researchers develop new treatment that extends telomeres

Will extending telomeres lead to longer, healthier lives? Researchers have taken an important step toward answering this question by developing a new treatment used in the laboratory that extends telomeres.

24 Jan 2015

SLU researcher discovers new information about how antibiotics stop staph infections

In research published in Proceedings of the National Academy of Sciences, assistant professor of biochemistry and molecular biology at Saint Louis University Mee-Ngan F. Yap, Ph.D., discovered new information about how antibiotics like azithromycin stop staph infections, and why staph sometimes becomes resistant to drugs.

23 Jan 2015

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

A natural protein made by immune cells may limit fibrosis and scarring in colitis, according to research published in the inaugural issue of Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

16 Jan 2015

Study finds difference between results from IHC and quantitative molecular techniques

The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.

12 Jan 2015

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.

From Precision NanoSystems Inc. 11 Jan 2015

DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.

9 Jan 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.

7 Jan 2015

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests.

18 Dec 2014

UTSA receives NIH grant to develop bioinformatics tools to find cause of breast cancer

According to the American Cancer Society, breast cancer is the most common cancer among American women, except for skin cancers, and about one in eight women in the United States will develop invasive breast cancer during their lifetime. The National Institutes of Health recently awarded a $1.08 million grant to The University of Texas at San Antonio to combine computational modeling with biological information to advance our understanding of what may cause breast cells to become cancerous.

16 Dec 2014

New MIT study implicates RNA-binding proteins in regulation of cancer

A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.

16 Dec 2014

Resveratrol in red wine inhibits formation of inflammatory factors that activate cardiovascular diseases

A natural substance present in red wine, resveratrol, inhibits the formation of inflammatory factors that trigger cardiovascular diseases. This has been established by a research team at the Department of Pharmacology of the University Medical Center of Johannes Gutenberg University of Mainz working in collaboration with researchers of the Friedrich Schiller University in Jena and the University of Vienna.

4 Dec 2014

Messenger RNA (mRNA) News and Research

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Recipients of The 2015 Protein Society Awards announced

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Two genetic mutations can interact to reduce risk for heart attack

Clusters of gene-blocking microRNAs can limit spread of cancer

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Researchers develop new treatment that extends telomeres

SLU researcher discovers new information about how antibiotics stop staph infections

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

Study finds difference between results from IHC and quantitative molecular techniques

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

DiaCarta raises $8 million in Series A financing from BVCF

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

UTSA receives NIH grant to develop bioinformatics tools to find cause of breast cancer

New MIT study implicates RNA-binding proteins in regulation of cancer

Resveratrol in red wine inhibits formation of inflammatory factors that activate cardiovascular diseases

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News